Abstract Purpose of Review Familial hypercholesterolemia (FH) is a hereditary condition
characterized by elevated levels of low-density lipoprotein cholesterol (LDL-C), which …

The exponential expansion of genomic data coupled with the lack of appropriate clinical
categorization of the variants is posing a major challenge to conventional medications for …

Introduction: The discovery of neurotrophic tyrosine receptor kinase (NTRK) gene fusions
has facilitated the development of precision oncology. Two first-generation NTRK inhibitors …

Familial hypercholesterolemia (FH) is caused by deleterious mutations in the LDLR that
increase markedly low-density lipoprotein (LDL) cholesterol and cause premature …

Due to the complex nature of noncovalent interactions and their long-range effects,
analyzing protein conformations using network theory can be enlightening. Protein Structure …

Abstract PCSK9 gain-of-function (GOF) variants increase degradation of low-density
lipoprotein receptor (LDLR) and are potentially associated with Familial …

Familial Hypercholesterolemia (FH) is a genetic disorder associated with premature
atherosclerosis and increased risk of cardiovascular diseases. LDLR deleterious mutations …

Familial hypercholesterolemia (FH) is a monogenic disease characterized by high plasma
low-density lipoprotein cholesterol (LDL-c) levels and increased risk of premature …

Background Familial hypercholesterolemia (FH) is caused by pathogenic variants in low-
density lipoprotein (LDL) receptor (LDLR) or its associated genes, including apolipoprotein …

Statins are the first-line treatment for familial hypercholesterolemia (FH), but response is
highly variable due to genetic and nongenetic factors. Here, we explored the association …